JSI RESOURCES: Publications

Human Papillomavirus Vaccine Introduction

SHARE THIS

Globally, cervical cancer kills more than 250,000 women every year and 85 percent of these deaths occur in low- and middle income countries. Two types of HPV cause 70 percent of cervical cancers and precancerous cervical lesions. When provided to young girls between 9 and 14 years old, the HPV vaccine is the most cost-effective public health measure to prevent HPV and therefore cervical cancer.

Since 2013 with funding from Gavi, the Vaccine Alliance, JSI has provided technical assistance to 7 countries introducing the human papilloma virus (HPV) vaccine nationwide. Vaccination efforts focused on reaching pre-adolescent/adolescent girls before they are at risk of exposure in Kenya, Cameroon, Zimbabwe, Tanzania, Madagascar, Malawi, and Mozambique. JSI also supported the HPV vaccination demonstration projects in Niger, Madagascar, and Zimbabwe.

JSI provides targeted technical assistance to HPV vaccine introduction efforts based on the needs and national roll-out plans in each country, in close collaboration with the Ministry of Health’s Expanded Program on Immunization (EPI), Ministry of Education (and other government programs), Gavi, WHO, UNICEF and other partners. JSI. 2019.

Partner with Us

We strive to build lasting relationships to produce better health outcomes for all.

Menu